Multi-Pathway Score Model for Tumor Heterogeneity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current approaches to treating tumors, including cancers, lack precision due to their heterogeneous nature, leading to ineffective therapies and wasted time, as they do not account for individualized tumor characteristics and dynamic changes in cellular signaling pathways.
Innovation Solution
A method to identify subjects at risk of clinical events by determining the activity levels of the PI3K, Wnt, and HH cellular signaling pathways using a Multi-Pathway Score (MPS) model, which calculates risk scores based on the expression levels of specific target genes, allowing for more accurate prediction and tailored therapeutic interventions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional empirical treatment approaches are used for tumors, then treatment simplicity is maintained, but treatment precision and effectiveness deteriorate due to tumor heterogeneity
Solution Approach 1:
The patent segments tumors into distinct molecular subtypes based on genomic, transcriptomic, proteomic, and metabolomic profiles. This segmentation allows for precise identification of tumor heterogeneity and enables tailored therapeutic strategies for each subtype, directly resolving the contradiction between treatment precision and approach complexity by providing a systematic framework for differentiation.
Solution Approach 2:
The patent changes the parameters used for tumor classification from traditional morphological and receptor-based criteria to multi-omics molecular profiles. This parameter transformation enables more precise tumor characterization and prediction of therapeutic response, achieving higher treatment precision while managing complexity through standardized molecular profiling protocols.
2Reliability
If multi-omics molecular profiling is implemented to account for tumor heterogeneity, then treatment precision improves, but time consumption and resource requirements increase
Solution Approach 1:
The patent performs molecular profiling and subtype classification as preliminary actions before treatment decisions are made. By establishing the molecular subtype early in the diagnostic process, the system enables timely and accurate therapeutic predictions without delaying treatment initiation, thus maintaining high reliability while minimizing time loss.
Solution Approach 2:
The patent incorporates feedback mechanisms where treatment response data is continuously collected and used to refine molecular subtype classifications and predictive models. This feedback loop improves therapeutic prediction reliability over time while optimizing the efficiency of molecular profiling by identifying the most informative markers for each tumor type.
3Productivity
If comprehensive molecular profiling is conducted to identify individualized tumor characteristics, then treatment effectiveness improves, but cost and resource requirements increase
Solution Approach 1:
The patent extracts and analyzes specific molecular markers and signatures from comprehensive multi-omics profiles that are most relevant for predicting therapeutic response to each treatment modality. By focusing on these key extracted features rather than processing all molecular data equally, the system achieves high treatment efficacy while reducing resource consumption through targeted analysis.
Solution Approach 2:
The patent develops a universal molecular profiling framework that can be applied across different tumor types and treatment modalities. This multi-functional approach allows the same core molecular assessment to inform multiple treatment decisions, improving treatment efficacy while amortizing resource costs across diverse clinical applications.
Data Source
AI summary
A bioinformatics method for determining a risk score that indicates a risk that a subject will experience a negative clinical event within a certain period of time. The risk score is based on a combination of activities of two or more cellular signaling pathways in a subject, such as a human, wherein the specific cellular signaling pathways are the PI3K pathway and one or more of a Wnt pathway, an ER pathway, and an HH pathway. The invention also includes an apparatus with a digital processor configured to perform such a method, to a non-transitory storage medium storing instructions that are executable by a digital processing device to perform such a method, and to a computer program comprising program code means for causing a digital processing device to perform such a method. The invention achieves advanced prognosis of negative clinical events, for example, disease progression, recurrence, development of metastasis, or even death.